SCHEMBL1197347

SCHEMBL1197347

COC(=O)Nc1ccc(-c2c[nH]c(CC(NC(=O)OC(C)(C)C)c3cnn(C)c3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
CYP17A1 P05093 2/20 0.36
PTPRB P23467 2/20 0.35
NTRK1 P04629 2/20 0.34
RET P07949 2/20 0.34
EPHB2 P29323 2/20 0.34
KDR P35968 2/20 0.34
ITGA4 P13612 1/20 0.34
ITGB7 P26010 1/20 0.34
F11 P03951 2/20 0.34
USP30 Q70CQ3 1/20 0.34
TNIK Q9UKE5 1/20 0.34
PSMB8 P28062 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
SSTR3 P32745 1/20 0.34
RORC P51449 1/20 0.34
CD274 Q9NZQ7 1/20 0.33
SREBF2 Q12772 1/20 0.33
MDM2 Q00987 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1196086 0.91 CYP17A1 (0.37) CYP17A1PTPRBITGA4ITGB7F11
SCHEMBL1196925 0.86 PTPRB (0.43) CYP17A1PTPRBF11SSTR3
SCHEMBL1195825 0.84 CYP17A1 (0.36) CYP17A1PTPRBF11PSMB8SSTR3
SCHEMBL1196594 0.84 F11 (0.41) GSK3BDYRK1ACYP17A1ITGA4ITGB7
SCHEMBL1197344 0.83 GSK3B (0.40) GSK3BDYRK1ACYP17A1PTPRBNTRK1
SCHEMBL1195824 0.76 CYP17A1 (0.36) CYP17A1PTPRBF11PSMB8SSTR3
SCHEMBL1196083 0.75 PTPRB (0.37) CYP17A1PTPRBF11SSTR3RORC
SCHEMBL3605569 0.75 CYP17A1 (0.44) CYP17A1PSMB8MAPKAPK2SREBF2
SCHEMBL1196847 0.75 F11 (0.40) CYP17A1ITGA4ITGB7F11MAPKAPK2
SCHEMBL1197796 0.74 CYP17A1 (0.40) CYP17A1PTPRBPSMB8SSTR3SREBF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604056-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-12-10 US disclosed
US-20120270853-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-10-25 US disclosed
US-8252830-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-28 US disclosed
EP-1981854-B1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-06-01 EP disclosed
US-20110028446-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-02-03 US disclosed
US-7842708-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-30 US disclosed
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-28 US disclosed
US-7626039-B2 Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-01 US disclosed
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB CO. 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270853-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 GSK3B 1305/4885DYRK1A 295/4885CYP17A1 1920/4885
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 GSK3B 1305/4885DYRK1A 295/4885CYP17A1 1920/4885
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 GSK3B 1305/4885DYRK1A 295/4885CYP17A1 1920/4885
US-20110028446-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 GSK3B 1305/4885DYRK1A 295/4885CYP17A1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.